Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition
These findings highlight Tempol's potential to mitigate oxidative stress and apoptosis linked to MTX therapy, supporting its use as an adjunctive treatment to protect bone health in patients undergoing MTX therapy. Emphasizing Tempol's clinical implications as a protective agent reinforces the urgency for further research into its long-term effects on cellular viability and bone integrity in the context of chemotherapy.
Authors
- Halil Mahir Kaplan (ORCID: https://orcid.org/0000-0002-1911-7327)
- Muhammed Altun (ORCID: https://orcid.org/0000-0002-0387-1819)
- Ahmet Can Haskan (ORCID: https://orcid.org/0000-0002-5575-3785)
- Soner Mete
- Fariz Selimli
- Meryem Taş Reyhanioğlu
Institutions
- Nevşehir Hacı Bektaş Veli University (TR)
- Mustafa Kemal University (TR)
- Cukurova University (TR)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/dddt.s510206
- Citations
- 4
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 3.19